Restrictive versus standard IV fluid therapy in adult ICU patients with septic shock—Bayesian analyses of the CLASSIC trial

Author:

Sivapalan Praleene123ORCID,Meyhoff Tine Sylvest13ORCID,Hjortrup Peter Buhl34ORCID,Lange Theis35ORCID,Kaas‐Hansen Benjamin Skov135ORCID,Kjær Maj‐Brit N.123ORCID,Laake Jon Henrik36ORCID,Cronhjort Maria37ORCID,Jakob Stephan M.8ORCID,Cecconi Maurizio910ORCID,Nalos Marek11ORCID,Ostermann Marlies312ORCID,Malbrain Manu L. N. G.13ORCID,Møller Morten Hylander123ORCID,Perner Anders123ORCID,Granholm Anders123ORCID

Affiliation:

1. Department of Intensive Care Copenhagen University Hospital—Rigshospitalet Copenhagen Denmark

2. Deptartment of Clinical Medicine Faculty of Health and Medical Science, University of Copenhagen Copenhagen Denmark

3. Collaboration for Research in Intensive Care (CRIC) Copenhagen Denmark

4. Department of Cardiothoracic Anaesthesia and Intensive Care, The Heart Center Copenhagen University Hospital—Rigshospitalet Copenhagen Copenhagen Denmark

5. Department of Public Health, Section of Biostatistics University of Copenhagen Copenhagen Denmark

6. Department of Intensive Care Oslo University Hospital Oslo Norway

7. Department of Clinical sciences, Danderyd Hospital Karolinska Institutet Stockholm Sweden

8. University of Bern Bern Switzerland

9. Biomedical Sciences Department Humanitas University Milan Italy

10. Department of Anaesthesia and Intensive Care IRCCS‐Humanitas Research Hospital Milan Italy

11. Department of Intensive Care University Hospital Pilsen Pilsen Czech Republic

12. Department of Intensive Care Guy's and St Thomas’ Hospital London UK

13. First Department of Anaesthesiology and Intensive Therapy Medical University of Lublin Lublin Poland

Abstract

AbstractBackgroundThe CLASSIC trial assessed the effects of restrictive versus standard intravenous (IV) fluid therapy in adult intensive care unit (ICU) patients with septic shock. This pre‐planned study provides a probabilistic interpretation and evaluates heterogeneity in treatment effects (HTE).MethodsWe analysed mortality, serious adverse events (SAEs), serious adverse reactions (SARs) and days alive without life‐support within 90 days using Bayesian models with weakly informative priors. HTE on mortality was assessed according to five baseline variables: disease severity, vasopressor dose, lactate levels, creatinine values and IV fluid volumes given before randomisation.ResultsThe absolute difference in mortality was 0.2%‐points (95% credible interval: −5.0 to 5.4; 47% posterior probability of benefit [risk difference <0.0%‐points]) with restrictive IV fluid. The posterior probabilities of benefits with restrictive IV fluid were 72% for SAEs, 52% for SARs and 61% for days alive without life‐support. The posterior probabilities of no clinically important differences (absolute risk difference ≤2%‐points) between the groups were 56% for mortality, 49% for SAEs, 90% for SARs and 38% for days alive without life‐support. There was 97% probability of HTE for previous IV fluid volumes analysed continuously, that is, potentially relatively lower mortality of restrictive IV fluids with higher previous IV fluids. No substantial evidence of HTE was found in the other analyses.ConclusionWe could not rule out clinically important effects of restrictive IV fluid therapy on mortality, SAEs or days alive without life‐support, but substantial effects on SARs were unlikely. IV fluids given before randomisation might interact with IV fluid strategy.

Funder

Læge Sophus Carl Emil Friis og hustru Olga Doris Friis' Legat

Novo Nordisk Fonden

Rigshospitalet

Publisher

Wiley

Subject

Anesthesiology and Pain Medicine,General Medicine

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3